Researchers identify the mutations that drive resistance to PI3K inhibitors in breast cancer, find they can be overcome
Secondary mutations within the PI3K/AKT pathway emerge throughout remedy with inavolisib and result in acquired resistance. A-B, Droplet digital PCR ...